Home / Health / Novartis Heart Drug Pelacarsen Fails Crucial Trial
Novartis Heart Drug Pelacarsen Fails Crucial Trial
5 Sep
Summary
- Novartis' experimental heart disease drug pelacarsen has failed a large clinical trial.
- The drug aimed to block the protein lipoprotein(a), a major heart disease risk factor.
- This failure raises questions about other similar drugs in development.
A large clinical trial for Novartis' experimental heart disease drug, pelacarsen, has unexpectedly failed. This outcome has sent shockwaves through the cardiology community, as the drug was anticipated to usher in a new era of heart attack and stroke prevention.
The drug targeted lipoprotein(a), a protein strongly linked to cardiovascular disease. Despite extensive prior research indicating that lowering Lp(a) would be protective, the clinical trial did not demonstrate the expected benefit. This marks a significant setback, particularly for individuals with elevated Lp(a) who adhere to healthy lifestyles but still face cardiovascular risks.
The trial, which spanned seven years and included 8,323 participants with pre-existing heart disease and high Lp(a) levels, was closely watched. Its failure casts uncertainty on the broader efforts by companies like Amgen and Eli Lilly, who are also developing similar Lp(a)-blocking drugs. The complete trial data is expected to be presented in November.
